Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2011

Norgine and Jubilant Ink Collaboration on Gastrointestinal Disease Drugs

  • Specialty pharma firm Norgine and Jubilant Biosys inked an initially three-year target discovery partnership to identify multiple targets against gastrointestinal diseases. The collaboration will generate a platform for Norgine to identify targets using Jubilant’s drug discovery platform. The latter will then develop preclinical candidates, to which Norgine will have all development and commercialization rights.

    Jubilant is a subisidary of Jubilant Life Sciences. The firm specializes in offering integrated discovery services to the global pharma and biotech industry. Operating an integrated discovery research facility, the firm has expertise in fields including discovery biology, medicinal chemistry, structural biology, ADME/Tox/pharmacology, molecular modeling, and IT. The firm’s Clinsys operation also provides global or regional clinical research activities spanning Phase I-IV trials, clinical data management, and biostatistics.

    Netherlands-based Norgine is developing a portfolio of internal development projects focused on gastroenterology, hepatology, and incontinence, but also offers development and commercialization partnerships for pharmaceuticals across Europe. In August the firm signed a development partnership with Alimentary Health (AH) to evaluate AH’s probiotic platform for potential development as a treatment for gastrointestinal disorders. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »